Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “bivalent”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources

Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease.

At present the only FDA-approved therapy for Alzheimer's disease involves the administration of acetylcholinesterase inhibitors, to alleviate the cholinergic deficit associated with this disease. However, none of the approved drugs is ideal in efficacy or tolerability. One possible strategy to improve selectivity and potency is to design drugs that can simultaneously bind to the catalytic and peripheral anionic sites of AChE. In this review we will describe the development of dimeric AChE inhibitors, from the early observations of high inhibition potency by bis-quaternary inhibitors, to the structure-based design of dimers based on tacrine, huperzine A, galanthamine, and polyamines.

Alzheimer Disease↗

Some aspects of the pharmacology of diphenyleneiodonium, a bivalent iodine compound.

1. Previous studies have established that diphenyleneiodonium binds to and inhibits the respiratory enzyme NADH dehydrogenase and also catalyses an exchange of Cl- for OH- across membranes. 2. The hypoglycaemia produced by diphenyleneiodonium was confirmed and shown to be reversible at a dose of 4 mg/kg in starved rats. 3. The lethality of diphenyleneiodonium in mice was cumulative. 4. Presumably as a result of the Cl-/OH- exchange, diphenyleneiodonium-treated rats excreted less Cl- than controls in the first 12 h after administration. However, the swelling of erythrocytes observed in vitro did not occur in vivo. 5. When [125I]diphenyleneiodonium was administered to rats and rabbits, its distribution did not appear to be governed by its binding to NADH dehydrogenase. Reasons for this are discussed. 6 Over 90% of the radioactivity excreted in the faeces of rabbits could not be extracted with boiling water or with dil. HNO3.

Animals↗

Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori.

AIM: To construct a recombinant vector which can express outer membrane protein (OMP) with M(r)18,000 and heat shock protein A (HspA) from Helicobacter pylori (H. pylori) in E. coli BL21, and to exploit the possibility for obtaining the vaccine conferring protection from H. pylori infection. METHODS: The target gene of HspA was amplified from H. pylori chromosome by PCR, and then inserted into the prokaryotic expression vector pET32a (+) by restrictive endonuclease enzyme kpn I, BamH I simultaneously. The recombinant vector was used to sequence, and then together with pET32a (+)/Omp(18), digested by restrictive endonuclease enzyme Hind III and BamH I simultaneously. pET32a(+)/HspA and Omp(18) were recovered from 1 % agarose gel by gel kit, and ligated with T(4) ligase by BamH I digested viscidity end. The recombinant plasmid of pET32a(+)/HspA/Omp(18) was transformed and expressed in E. coli BL21 (DE3) under induction of IPTG. After purification, its antigenicity of the fusion protein was detected by Western blot. RESULTS: Enzyme digestion analysis and sequencing showed that the target genes were inserted into the recombinant vector, composed of 891 base pairs, encoded objective polypeptides of 297 amino acid residues. Compared with GenBank reported by Tomb et al, there were 1.3 % and 1.4 % differences in obtained H. pylori nucleotide sequence and amino acid residues, respectively. SDS-PAGE analysis showed that relative molecule mass (M(r)) of the expressed product was M(r) 51,000, M(r) of protein expressed by pET32a (+) was about M(r) 20,000, and soluble expression product accounted for 18.96 % of total bacterial protein. After purification with Ni(+2)-NTA agarose resins, the purification of recombinant fusion protein was about 95 %. Western blot showed that recombinant fusion protein could be recognized by the patients' serum infected with H. pylori and anti-Omp(18) monoclone, suggesting that this protein had good antigenicity. CONCLUSION: The gene coding for H. pylori M(r)18,000 OMP and HspA was cloned and expressed successfully. The results obtained lay the foundation for development of H. pylori protein vaccine and a quick diagnostic kit.

Bacterial Outer Membrane Proteins↗

Participation of bivalent ions in the acetylcholine-provoked gastric smooth-muscle phasis contractions.

Experiments were carried out on muscle strips from cat antrum. Acetylcholine added to Ca++ -free medium containing EDTA (10-5M) exerted no effect on the phasic contractions of the gastric smooth muscle. Ba++at low concentrations (0,1 to 0,5mM) replaced Ca++with respect to the acetylcholine effect. On the background of blocked cholinergic (atropine 10-5M) and adrenergic (phentolamine 10-5 M and propranolol 10-5M) structures Ba++ provoked slow potentials and cotractions with a frequency of 9 to 10 cpm. delta600 (10-5M) blocked the Ba++-induced myogenic electrical and contractile activities of the smooth muscle. The role of the cholinergic structures for synchronizing the electrical and contractile activities of the smooth muscle is considered.

Acetylcholine↗

[Ratio of concentration of ions of uni- and bivalent metals in the tissues of developing chick embryos and 1-day-old chickens].

The ratio of concentrations Na+/K+ decreases in the brain and liver and increases in the cardiac muscle during the chick embryogenesis. The maximum concentration of Ca2+ was noted in the tissues under study on 14th day of chick embryonic development and its content decreased reliably at the subsequent stages. The concentration of Mg2+ in the tissues under study decreased during the embryogenesis as well.

Animals↗

Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.

Immunization with GMK vaccine (G(M2) ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti-G(M2) antibodies in close to 100% of patients. We found previously that anti-G(D2) antibodies could be induced in some patients using G(D2)-keyhole limpet hemocyanin + QS-21 (GDK). In this trial, we wished: (a) to determine whether immunization with both GMK and GDK vaccines could induce antibodies against both G(M2) and G(D2); and (b) to determine the optimal dose of GDK. Thirty-one patients with melanoma or sarcoma who had no evidence of disease after complete surgical resection were immunized with both GMK (30 microg of G(M2)) and GDK on weeks 1, 2, 3, 4, 12, 24, and 36. Patients were assigned to one of five GDK dose levels (3, 10, 30, 70, or 130 microg of G(D2)). Anti-G(M2) IgM or IgG were induced in 97% of patients. The dose of GDK did not affect the anti-G(M2) response, although at the highest GDK dose level, 3 of 7 patients did not make anti-G(M2) IgG. GDK was less immunogenic; overall 45% of patients developed either IgM or IgG against G(D2). At GDK doses of 30 or 70 microg, 8 of 11 patients (73%) made either IgM or IgG anti-G(D2) antibodies. We conclude that both GMK and GDK vaccines can induce antibodies against G(M2) and G(D2) in a majority of patients and are safe. The optimal dose of GDK appears to be either 30 or 70 microg when administered with GMK vaccine.

Cancer Vaccines↗

Modification of acetylcholine action by bivalent cations on the perfused heart of the frog.

When frog heart is perfused with high calcium Ringer solution it may be stimulated by a low dose of acetylcholine. This stimulant action is mediated through atropine-sensitive receptors and is blocked by certain calcium antagonists such as local anesthetics, cobalt, magnesium, and phenoxybenzamine. However, the nicotinic action of high doses of acetylcholine on atropinized heart is not blocked by cobalt and magnesium ions.

Acetylcholine↗

[Effect of hexammine cobaltchloride on the transport of bivalent cations in liver mitochondria].

It is found that hexammine cobaltichloride (HAC) which interacts with anionic groups of sulphate-containing glycosamine glycanes, is a specific inhibitor of mitochondrial transport of Ca2+ (semi-maximal inhibition in the presence of 6 nmoles HAC/mg of protein) and Sr2+ (semi-maximal inhibition in the presence of 30 nmoles HAC/mg of protein). Mn2+ translocation was inhibited by considerably higher HAC concentrations, 4-fold increase in the transport rate being observed in the presence of 15 nmoles/mg of protein. Inhibition of Ca2+ translocation is competitive, and its inhibition constant is 6-10(-6) M. HAC (3-120 muM) does not affect respiration, oxidative phosphorylation and DNP-stimulated ATPase activity of liver mitochondria, but at the concentration of 15 muM it decreases markedly the activity of "detergent" ATPase from liver mitochondria. It is suggested that the effect of HAC is due to its interaction with anionic groups of mitochondrial glycoproteins.

Adenosine Triphosphatases↗

A bivalent leukotriene B(4) antagonist for scintigraphic imaging of infectious foci.

UNLABELLED: Several radiolabeled chemotactic peptides have been tested for their suitability to show infection and inflammation. Leukotriene B(4) (LTB(4)) receptor-binding ligands could be useful agents for revealing neutrophilic infiltrations because the LTB(4) receptor is abundantly expressed on neutrophils after an inflammatory stimulus. In this study, we investigated the in vivo and in vitro characteristics of a new hydrophilic (111)In-labeled LTB(4) antagonist. METHODS: The LTB(4) antagonist DPC11870-11 was labeled with (111)In and intravenously injected into New Zealand White rabbits with Escherichia coli infection in the left thigh muscle. The pharmacokinetics and biodistribution were studied by serial scintigraphic imaging (0-24 h after injection) and by ex vivo counting of dissected tissues (6 and 24 h after injection). The receptor-mediated in vivo localization of the compound was investigated in 3 rabbits that received an excess of nonradioactive indium-labeled agent 2 min before the administration of the (111)In-labeled LTB(4) antagonist. RESULTS: In rabbits with intramuscular E. coli infection, the abscess was visualized as early as 2 h after injection. Accumulation in the abscess increased with time, resulting in excellent images at 6 h after injection. Blood clearance was rapid in the first hours after injection (alpha-half-life = 30 +/- 6 min, 85%; beta-half-life = 25.7 +/- 0.8 h, 15%). Abscess-to-background ratios, as derived from the region-of-interest analysis, increased to 34 +/- 7 at 24 h after injection. The images of both groups showed moderate uptake in the liver, spleen, kidneys, and bone marrow. No activity was seen in the bladder, indicating almost complete retention in the kidneys. The uptake in the abscess could be blocked completely by injection of an excess of nonradioactive agent, indicating a specific receptor-ligand interaction of the radiolabeled agent in the infected tissue. Biodistribution data showed that after saturation of the LTB(4) receptor, the abscess uptake, in percentage injected dose per gram, was significantly reduced (0.03 +/- 0.02 vs. 0.24 +/- 0.06, P = 0.008). CONCLUSION: The modified LTB(4) antagonist showed infectious foci rapidly after injection because of specific receptor-ligand interaction. Because of the high abscess-to-background ratios that were obtained and the fact that no accumulation of radioactivity was observed in the gastrointestinal tract, this compound has excellent characteristics for revealing infectious and inflammatory foci.

Animals↗